Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD 50.09 M

Veracyte, Inc. EBITDA is USD 50.09 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -213.04% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -44.31 M, a 4,041.59% change year over year.
  • Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -1.07 M, a -95.64% change year over year.
  • Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -24.55 M, a -58.87% change year over year.
  • Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -59.69 M, a 256.11% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)